Einträge von Reuken, Philipp A. auf dem Publikationsserver

Khaled, Najib Ben, Seidensticker, Max, Ricke, Jens, Mayerle, Julia, Oehrle, Bettina, Rössler, Daniel, Teupser, Daniel, Ehmer, Ursula, Bitzer, Michael , Waldschmidt, Dirk, Fuchs, Martin, Reuken, Philipp A., Lange, Christian M., Wege, Henning, Kandulski, Arne, Dechene, Alexander, Venerito, Marino, Berres, Marie-Luise, Luedde, Tom , Kubisch, Ilja, Reiter, Florian P. und De Toni, Enrico N. (2022) Atezolizumab and bevacizumab with transarterial chemoembolization in hepatocellular carcinoma: the DEMAND trial protocol. Future Oncology 18 (12), S. 1423-1435. Volltext nicht vorhanden.

Brozat, Jonathan F. , Hanses, Frank, Haelberger, Martina, Stecher, Melanie, Dreher, Michael, Tometten, Lukas, Ruethrich, Maria M., Vehreschild, Janne J. , Trautwein, Christian, Borgmann, Stefan, Vehreschild, Maria J. G. T. , Jakob, Carolin E. M., Stallmach, Andreas, Wille, Kai, Hellwig, Kerstin, Isberner, Nora, Reuken, Philipp A., Geisler, Fabian, Nattermann, Jacob und Bruns, Tony (2022) COVID‐19 mortality in cirrhosis is determined by cirrhosis‐associated comorbidities and extrahepatic organ failure: Results from the multinational LEOSS registry. United European Gastroenterology Journal 10 (4), S. 409-424.

Bruns, Tony , Peter, Jack, Reuken, Philipp A., Grabe, Dominik H., Schuldes, Sonja R., Brenmoehl, Julia, Schölmerich, Jürgen, Wiest, Reiner und Stallmach, Andreas (2012) NOD2 gene variants are a risk factor for culture‐positive spontaneous bacterial peritonitis and monomicrobial bacterascites in cirrhosis. Liver International 32 (2), S. 223-230. Volltext nicht vorhanden.